Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1A1 | Q02108 | 17/20 | 0.66 |
| ▸ | GUCY1B1 | Q02153 | 17/20 | 0.66 |
| ▸ | PDE5A | O76074 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13733662 | 0.90 | GUCY1A1 (0.57) | GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL25975483 | 0.89 | GUCY1A1 (0.64) | GUCY1A1GUCY1B1 | |
| SCHEMBL25975302 | 0.89 | GUCY1A1 (0.64) | GUCY1A1GUCY1B1 | |
| SCHEMBL25975531 | 0.87 | GUCY1A1 (0.59) | GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL25975532 | 0.87 | GUCY1A1 (0.59) | GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL25975605 | 0.87 | GUCY1A1 (0.59) | GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL25975070 | 0.87 | GUCY1A1 (0.59) | GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL25975069 | 0.87 | GUCY1A1 (0.59) | GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL25974982 | 0.87 | GUCY1A1 (0.59) | GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL327087 | 0.86 | GUCY1A1 (0.72) | GUCY1A1GUCY1B1PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2699578-B1 | FLUOROALKYL-SUBSTITUTED PYRAZOLOPYRIDINES AND USE THEREOF | BAYER IP GMBH (DE) | 2016-04-20 | — | — | EP | disclosed |
| EP-2699578-B1 | FLUOROALKYL-SUBSTITUTED PYRAZOLOPYRIDINES AND USE THEREOF | BAYER IP GMBH (DE) | 2016-04-20 | — | — | EP | disclosed |
| EP-2590987-B1 | CONDENSED 4-AMINOPYRIMIDINES AND THEIR USE AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE | BAYER IP GMBH (DE) | 2016-03-09 | — | — | EP | disclosed |
| US-9090610-B2 | Fluoroalkyl-substituted pyrazolopyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-28 | — | — | US | disclosed |
| US-9090610-B2 | Fluoroalkyl-substituted pyrazolopyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-28 | — | — | US | disclosed |
| US-9090610-B2 | Fluoroalkyl-substituted pyrazolopyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-28 | — | — | US | disclosed |
| US-8765769-B2 | Ring-fused 4-aminopyrimidines and use thereof as stimulators of soluable guanylate cyclases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-8765769-B2 | Ring-fused 4-aminopyrimidines and use thereof as stimulators of soluable guanylate cyclases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-8765769-B2 | Ring-fused 4-aminopyrimidines and use thereof as stimulators of soluable guanylate cyclases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-20140100229-A1 | FLUOROALKYL-SUBSTITUTED PYRAZOLOPYRIDINES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-10 | — | — | US | disclosed |
| US-20130172372-A1 | RING-FUSED 4-AMINOPYRIMIDINES AND USE THEREOF AS STIMULATORS OF SOLUABLE GUANYLATE CYCLASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
| US-20130172372-A1 | RING-FUSED 4-AMINOPYRIMIDINES AND USE THEREOF AS STIMULATORS OF SOLUABLE GUANYLATE CYCLASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
| US-20130172372-A1 | RING-FUSED 4-AMINOPYRIMIDINES AND USE THEREOF AS STIMULATORS OF SOLUABLE GUANYLATE CYCLASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
| WO-2012004259-A1 | RING-FUSED 4 -AMINOPYRIMIDINES AND USE THEREOF AS STIMULATORS OF SOLUABLE GUANYLATE CYCLASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172372-A1 | RING-FUSED 4-AMINOPYRIMIDINES AND USE THEREOF AS STIMULATORS OF SOLUABLE GUANYLATE CYCLASES | GUCY1B1, GUCY1A2, GUCY1B2 | GUCY1A1 4/4885GUCY1B1 1/4885PDE5A 15/4885 |
| US-20140100229-A1 | FLUOROALKYL-SUBSTITUTED PYRAZOLOPYRIDINES AND USE THEREOF | PON1, QDPR, FABP3 | GUCY1A1 2148/4885GUCY1B1 1166/4885PDE5A 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.